PCMA: 'It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to PCMA: 'It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing'

Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand

August 29, 2016 6:06 AM EDT

Mylan N.V. (Nasdaq: MYL) announced that its U.S. subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton... More

Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC

August 26, 2016 8:15 AM EDT

Bill Ackman says Valeant Pharma (NYSE: VRX) has made a lot of progress and that a passive position was a "mistake," according to commentary on CNBC today. The investor says Valeant is now a "classic" Pershing Square investment.

... More